# Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

> **NCT01462357** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1079 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix
- **BIOLOGICAL:** Gardasil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01462357
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-21
- **Primary completion:** 2015-10-27
- **Final completion:** 2015-10-27
- **Target enrollment:** 1079 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462357, "Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01462357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*